EGFR and cancer: Some resistance mechanisms have been discovered including the T790M secondary mutation in EGFR,7MET-amplification,8FGFR1 overexpression,9, 10IGF1R overexpression and gain of cancer stem cell and EMT features.11 Inhibitors targeting MET,12FGFR112 and T790M-mutated EGFR13, 14 are currently under clinical investigation and may facilitate treatment of EGFR-TKI resistance in future settings.